Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
Antivirals are urgently needed to treat patients with Acute Respiratory Distress Syndrome (ADRS).
SARS-CoV-2 attaches to cells via the cell surface form of ACE2 expressed at relatively low levels in the lung.
Inhibitors that prevent the interaction with ACE2 or prevent its internalisation are hypothesised to be candidate antiviral agents for COVID-19.
In collaboration with Monash University, Department of Pharmacology and Department of Biochemistry, we will screen ACE2 inhibitors for their ability to prevent viral entry and replication, examine their mechanism of action and optimise the best performing candidates for formulation as an inhalant.
2020 -
For any general enquiries relating to this project, please contact:
Co-Program Director, Disease Elimination; Scientific Director, Burnet Diagnostics Initiative; Principal Investigator, Burnet Vaccine Initiative; Co-Head, Viral Entry and Vaccines Group
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2023 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
